Search bioRxiv⌕ Search

Biology subjects

Malloizel-Delaunay, J.

Publications and source records attributed to Malloizel-Delaunay, J..

2 recordsLinked to original sources

Lymphangiogenesis in Abdominal Aortic Aneurysm regulates the balance between resident and circulating eosinophils via a 15-lipoxygenase-dependent mechanism

The abdominal aortic aneurysm (AAA) is a chronic degeneration of the aortic wall involving an inflammatory response, aberrant remodeling of the extracellular matrix, and the development of microvessels. Among these, lymphatic capillaries develop in the adventitia. However, the role of lymphangiogenesis in AAA remains unclear. Here, we confirmed the development of lymphatic vessels in both human and mouse AAA. This was associated with a decrease in specialized pro-resolving mediators (SPM) generated by 15-Lipoxygenase (15LO), an enzyme that controls resolution of inflammation in lymphatic diseases. Lymphatic selective depletion of 15LO (Prox1cre; Alox15fl/fl mice) increased both systemic and resident eosinophil (EOS) accumulation in lesions, but had no effect on other immune cell populations. Mechanistically, in vitro depletion of 15LO in lymphatic endothelial cells (LEC) significantly decreased EOS adhesion. In contrast, 15LO LEC depletion improved transendothelial migration. In vivo, the rescue of 15LO using lentivector transduction modified the balance between resident and systemic EOS in favor of the resident ones and reduced the AAA lesion. Altogether, we show that lymphatic vessels play a protective role in AAA by regulating the trafficking of EOS into the aorta wall.

cell biology↗

Apelin-VEGF-C mRNA delivery as therapeutic for the treatment of secondary lymphedema

Secondary lymphedema (LD) corresponds to a severe lymphatic dysfunction leading to the accumulation of fluid and fibrotic adipose tissue in a limb. Here, we identified apelin (APLN) as a powerful molecule for regenerating lymphatic function in LD. We identified the loss of APLN expression in lymphedematous arm compared to normal arm in patients. The role of APLN in LD was confirmed in APLN-knockout mice, in which LD is increased and associated with fibrosis and dermal backflow. This was reversed by intradermal injection of APLN-lentivectors. Mechanistically, APLN stimulates lymphatic endothelial cell gene expression and induces the binding of E2F8 transcription factor to the promoter of CCBE1 that controls VEGF-C processing. In addition, APLN induces Akt and eNOS pathways to stimulate lymphatic collector pumping. Our results show that APLN represents a novel partner for VEGF-C to restore lymphatic function in both initial and collecting vessels. As LD appears after cancer treatment, we validated the APLN-VEGF-C combination using a novel class of safe and non-integrative RNA-delivery LentiFlash(R) vector that will be evaluated for phase I/IIa clinical trial.

pathology↗